Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume – Should You Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw an uptick in trading volume on Wednesday . Approximately 1,886,695 shares were traded during trading, an increase of 166% from the previous session’s volume of 709,668 shares.The stock last traded at $3.7750 and had previously closed at $3.86.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Cantor Fitzgerald started coverage on shares of Inventiva in a research report on Friday, July 17th. They issued an “overweight” rating for the company. Piper Sandler restated an “overweight” rating on shares of Inventiva in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research note on Friday, July 17th. Finally, Guggenheim upped their price objective on Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $15.75.

Inventiva Price Performance

The business’s 50-day moving average is $4.56 and its 200 day moving average is $4.90.

Institutional Investors Weigh In On Inventiva

A number of hedge funds and other institutional investors have recently modified their holdings of IVA. Engineers Gate Manager LP raised its holdings in Inventiva by 155.5% during the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after buying an additional 43,280 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in Inventiva in the 4th quarter worth $603,000. Seven Fleet Capital Management LP bought a new stake in Inventiva in the 1st quarter worth $1,111,000. Eventide Asset Management LLC purchased a new position in shares of Inventiva in the fourth quarter valued at about $1,155,000. Finally, Simplify Asset Management Inc. purchased a new position in shares of Inventiva in the fourth quarter valued at about $1,570,000. Institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.